2020 Korean guidelines for the management of metastatic prostate cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, In-Ho | - |
dc.contributor.author | Shin, Sang Joon | - |
dc.contributor.author | Kang, Byung Woog | - |
dc.contributor.author | Kang, Jihoon | - |
dc.contributor.author | Kim, Dalyong | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Kim, Jin Young | - |
dc.contributor.author | Kim, Chan Kyu | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Park, Kwonoh | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Bae, Woo Kyun | - |
dc.contributor.author | Sohn, Byeong Seok | - |
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Lee, Jae Lyun | - |
dc.contributor.author | Lee, Junglim | - |
dc.contributor.author | Lim, Seung Taek | - |
dc.contributor.author | Lim, Joo Han | - |
dc.contributor.author | Chang, Hyun | - |
dc.contributor.author | Jung, Joo Young | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Cho, Jaeho | - |
dc.contributor.author | Joung, Jae Young | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.date.accessioned | 2021-11-20T12:40:59Z | - |
dc.date.available | 2021-11-20T12:40:59Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128117 | - |
dc.description.abstract | In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.Y | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | ANDROGEN-DEPRIVATION THERAPY | - |
dc.subject | SMALL-CELL CARCINOMA | - |
dc.subject | MITOXANTRONE PLUS PREDNISONE | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | PAINFUL BONE METASTASES | - |
dc.subject | POST HOC ANALYSIS | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | GETUG-AFU 15 | - |
dc.subject | ZOLEDRONIC ACID | - |
dc.subject | OPEN-LABEL | - |
dc.title | 2020 Korean guidelines for the management of metastatic prostate cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.identifier.doi | 10.3904/kjim.2020.213 | - |
dc.identifier.scopusid | 2-s2.0-85107083984 | - |
dc.identifier.wosid | 000646765900002 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.3, pp.491 - 514 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 36 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 491 | - |
dc.citation.endPage | 514 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002709201 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ANDROGEN-DEPRIVATION THERAPY | - |
dc.subject.keywordPlus | SMALL-CELL CARCINOMA | - |
dc.subject.keywordPlus | MITOXANTRONE PLUS PREDNISONE | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | PAINFUL BONE METASTASES | - |
dc.subject.keywordPlus | POST HOC ANALYSIS | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | GETUG-AFU 15 | - |
dc.subject.keywordPlus | ZOLEDRONIC ACID | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordAuthor | Practice guideline | - |
dc.subject.keywordAuthor | Prostate neoplasms | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.